Objective. We aimed to evaluate whether the differential gene expression profiles of patients with rheumatoid arthritis (RA) could distinguish responders from nonresponders to methotrexate (MTX) and, in the case of MTX nonresponders, responsiveness to MTX plus anti-tumor necrosis factor-alpha (anti-TNF) combined therapy. Methods. We evaluated 25 patients with RA taking MTX 15-20 mg/week as a monotherapy (8 responders and 17 nonresponders). All MTX nonresponders received intliximab and were reassessed after 20 weeks to evaluate their anti-TNF responsiveness using the European League Against Rheumatism response criteria. A differential gene expression analysis from peripheral blood mononuclear cells was performed in terms of hierarchical gene...
Our aim was to identify differentially expressed (DE) genes and biological processes that may help p...
It is well documented that patients affected by rheumatoid arthritis (RA) have distinct susceptibili...
Anti-tumor necrosis factor alpha (anti-TNF) biologic therapy is a widely used treatment for rheumato...
Objective. We aimed to evaluate whether the differential gene expression profiles of patients with r...
Methotrexate (MTX) monotherapy is a common first treatment for rheumatoid arthritis (RA), but many p...
About 70 genetic studies have already addressed the need of biomarkers to predict the response of pa...
Objective. To establish whether the analysis of whole-blood gene expression is useful in predicting ...
Methotrexate (MTX) monotherapy is a common first treatment for rheumatoid arthritis (RA), but many p...
As indicators of responsiveness to a tumour necrosis factor (TNF)alpha blocking agent (infliximab) a...
Background: There is a pressing need in rheumatoid arthritis (RA) to identify patients who will n...
Objective: This review will summarize pharmacogenetic studies of single nucleotide polymorphisms in ...
[Abstract] Background: Rheumatoid arthritis (RA) is the most frequent autoimmune disease involving t...
This study was supported by Medical Research Council (MRC) MR/K015346/1 MATURA study. ARUK 20670 MAT...
International audienceBackground: In the current context of personalized medicine, one of the major ...
<div><p>Approximately 30% of rheumatoid arthritis patients achieve inadequate response to anti-TNF b...
Our aim was to identify differentially expressed (DE) genes and biological processes that may help p...
It is well documented that patients affected by rheumatoid arthritis (RA) have distinct susceptibili...
Anti-tumor necrosis factor alpha (anti-TNF) biologic therapy is a widely used treatment for rheumato...
Objective. We aimed to evaluate whether the differential gene expression profiles of patients with r...
Methotrexate (MTX) monotherapy is a common first treatment for rheumatoid arthritis (RA), but many p...
About 70 genetic studies have already addressed the need of biomarkers to predict the response of pa...
Objective. To establish whether the analysis of whole-blood gene expression is useful in predicting ...
Methotrexate (MTX) monotherapy is a common first treatment for rheumatoid arthritis (RA), but many p...
As indicators of responsiveness to a tumour necrosis factor (TNF)alpha blocking agent (infliximab) a...
Background: There is a pressing need in rheumatoid arthritis (RA) to identify patients who will n...
Objective: This review will summarize pharmacogenetic studies of single nucleotide polymorphisms in ...
[Abstract] Background: Rheumatoid arthritis (RA) is the most frequent autoimmune disease involving t...
This study was supported by Medical Research Council (MRC) MR/K015346/1 MATURA study. ARUK 20670 MAT...
International audienceBackground: In the current context of personalized medicine, one of the major ...
<div><p>Approximately 30% of rheumatoid arthritis patients achieve inadequate response to anti-TNF b...
Our aim was to identify differentially expressed (DE) genes and biological processes that may help p...
It is well documented that patients affected by rheumatoid arthritis (RA) have distinct susceptibili...
Anti-tumor necrosis factor alpha (anti-TNF) biologic therapy is a widely used treatment for rheumato...